References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA
Cancer J Clin. 2019;69(1):7-34.
2. Liang X, Bi S, Yang W, et al. Reprint of: Epidemiological serosurvey
of Hepatitis B in China–declining HBV prevalence due to Hepatitis B
vaccination. Vaccine. 2013;31 Suppl 9:J21-28.
3. Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating
hepatitis B disease, China. Bull World Health Organ.2019;97(3):230-238.
4. Nakamoto N, Cho H, Shaked A, et al. Synergistic reversal of
intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4
blockade. PLoS Pathog. 2009;5(2):e1000313.
5. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for
previously treated, PD-L1-positive, advanced non-small-cell lung cancer
(KEYNOTE-010): a randomised controlled trial. The Lancet.2016;387(10027):1540-1550.
6. Pu D, Yin L, Zhou Y, et al. Safety and efficacy of immune checkpoint
inhibitors in patients with HBV/HCV infection and advanced-stage cancer:
A systematic review. Medicine (Baltimore). 2020;99(5):e19013.
7. Byeon S, Cho JH, Jung HA, et al. PD-1 inhibitors for non-small cell
lung cancer patients with special issues: Real-world evidence.Cancer Med. 2020;9(7):2352-2362.
8. Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy
for previously untreated, PD-L1-expressing, locally advanced or
metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised,
open-label, controlled, phase 3 trial. The Lancet.2019;393(10183):1819-1830.
9. Garassino MC, Gadgeel S, Esteban E, et al. Patient-reported outcomes
following pembrolizumab or placebo plus pemetrexed and platinum in
patients with previously untreated, metastatic, non-squamous
non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind,
randomised, placebo-controlled, phase 3 trial. The Lancet
Oncology. 2020;21(3):387-397.
10. Paz-Ares L, Vicente D, Tafreshi A, et al. A Randomized,
Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients
With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of
KEYNOTE-407. J Thorac Oncol. 2020;15(10):1657-1669.
11. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in
Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med.2015;373(2):123-135.
12. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in
Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med.2015;373(17):1627-1639.
13. Chajon E, Castelli J, Marsiglia H, De Crevoisier R. The synergistic
effect of radiotherapy and immunotherapy: A promising but not simple
partnership. Crit Rev Oncol Hematol. 2017;111:124-132.
14. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of
non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028.